PL1781649T3 - Podstawione hydantoiny - Google Patents

Podstawione hydantoiny

Info

Publication number
PL1781649T3
PL1781649T3 PL05771890T PL05771890T PL1781649T3 PL 1781649 T3 PL1781649 T3 PL 1781649T3 PL 05771890 T PL05771890 T PL 05771890T PL 05771890 T PL05771890 T PL 05771890T PL 1781649 T3 PL1781649 T3 PL 1781649T3
Authority
PL
Poland
Prior art keywords
substituted hydantoins
hydantoins
substituted
Prior art date
Application number
PL05771890T
Other languages
English (en)
Polish (pl)
Inventor
Xin-Jie Chu
Nader Fotouhi
Nicholas John Silvester Huby
Norman Kong
Lee Apostle Mcdermott
John Anthony Moliterni
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1781649T3 publication Critical patent/PL1781649T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL05771890T 2004-08-17 2005-08-09 Podstawione hydantoiny PL1781649T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US68299705P 2005-05-20 2005-05-20
EP05771890A EP1781649B1 (en) 2004-08-17 2005-08-09 Substituted hydantoins
PCT/EP2005/008633 WO2006018188A2 (en) 2004-08-17 2005-08-09 Substituted hydantoins

Publications (1)

Publication Number Publication Date
PL1781649T3 true PL1781649T3 (pl) 2009-01-30

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05771890T PL1781649T3 (pl) 2004-08-17 2005-08-09 Podstawione hydantoiny

Country Status (16)

Country Link
US (1) US7427635B2 (OSRAM)
EP (1) EP1781649B1 (OSRAM)
JP (1) JP4927733B2 (OSRAM)
KR (2) KR100889721B1 (OSRAM)
AR (1) AR050297A1 (OSRAM)
AT (1) ATE404556T1 (OSRAM)
AU (1) AU2005274390B2 (OSRAM)
BR (1) BRPI0514515A (OSRAM)
CA (1) CA2576599A1 (OSRAM)
DE (1) DE602005008986D1 (OSRAM)
ES (1) ES2313389T3 (OSRAM)
MX (1) MX2007001846A (OSRAM)
PL (1) PL1781649T3 (OSRAM)
RU (1) RU2383542C2 (OSRAM)
TW (1) TW200621764A (OSRAM)
WO (1) WO2006018188A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
EP2188276B1 (en) * 2007-08-16 2012-03-28 F. Hoffmann-La Roche AG Substituted hydantoins
BRPI0820696A2 (pt) 2007-12-20 2019-09-24 Hoffmann La Roche hidantoínas substituídas como inibidores de cinase de mek
US8592465B2 (en) * 2008-06-16 2013-11-26 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
TW201113280A (en) * 2009-07-03 2011-04-16 Nensius Res As Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
EP2542081A4 (en) 2010-03-01 2013-07-31 Gtx Inc COMPOSITIONS FOR CANCER TREATMENT
JP5985401B2 (ja) 2010-03-09 2016-09-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法
BR112012027762B1 (pt) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh Derivados de cetoheteroarilpiperidina e - piperazina como fungicidas
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
BR112021004999A2 (pt) * 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
KR20210116325A (ko) * 2020-03-13 2021-09-27 영진약품 주식회사 티아졸 유도체 또는 이의 약제학적으로 허용가능한 염을 포함하는 암의 예방 또는 치료용 약학 조성물
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
BR9810366A (pt) 1997-07-01 2000-08-29 Warner Lambert Co Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
DK1280801T3 (da) * 2000-05-03 2006-01-23 Hoffmann La Roche Hydantoinholdige glucokinaseaktivatorer
NZ530524A (en) * 2001-07-19 2006-12-22 Pharmacia Italia S Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
MX2007001846A (es) 2007-03-28
ES2313389T3 (es) 2009-03-01
US20060041146A1 (en) 2006-02-23
WO2006018188A3 (en) 2006-05-18
JP2008509950A (ja) 2008-04-03
KR100889721B1 (ko) 2009-03-23
RU2007109651A (ru) 2008-09-27
JP4927733B2 (ja) 2012-05-09
RU2383542C2 (ru) 2010-03-10
BRPI0514515A (pt) 2008-06-10
EP1781649A2 (en) 2007-05-09
ATE404556T1 (de) 2008-08-15
AR050297A1 (es) 2006-10-11
KR20070034635A (ko) 2007-03-28
AU2005274390B2 (en) 2012-01-19
AU2005274390A1 (en) 2006-02-23
EP1781649B1 (en) 2008-08-13
US7427635B2 (en) 2008-09-23
WO2006018188A2 (en) 2006-02-23
CA2576599A1 (en) 2006-02-23
TW200621764A (en) 2006-07-01
KR20090006885A (ko) 2009-01-15
DE602005008986D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
IL205159A0 (en) Imidazole compounds
IL181732A0 (en) 2-morpholino-4-pyrimidone compound
IL187279A0 (en) Hydantoin compounds
PL1781649T3 (pl) Podstawione hydantoiny
GB0415663D0 (en) Compound
EP1732560A4 (en) SUBSTITUTED CINNOLINE-4-YLAMINE
IL180888A0 (en) Substituted n-acyl-2-aminothiazoles
GB0408771D0 (en) Compound
GB0405193D0 (en) Compounds
AP2006003766A0 (en) Novel imidazoles
GB0401269D0 (en) Compounds
GB0421106D0 (en) Compound
GB0405101D0 (en) Compounds
GB0408772D0 (en) Compounds
ZA200700723B (en) Substituted N-acyl-2-aminothiazoles
GB0411562D0 (en) Compound
GB0425969D0 (en) Compound
GB0403593D0 (en) Compounds
GB0428295D0 (en) Compound
GB0403595D0 (en) Compounds
ZA200703075B (en) Imidazole compound
GB0419315D0 (en) Compounds
GB0401654D0 (en) Compounds
GB0400695D0 (en) Compounds
GB0401653D0 (en) Compounds